The Consent Revolution: Can UK's PKB Disrupt the US Health Data Market?

CAMBRIDGE, UK – October 27, 2026 – For decades, the American healthcare system has treated patient data as an institutional asset—a commodity to be hoarded, traded, or grudgingly shared between enterprise software giants. But as the digital health sector converges on Las Vegas for the HLTH 2026 conference this November, a British pioneer is arriving with a radically different proposition: what if the patient actually held the keys?

Patients Know Best (PKB), the UK-based patient-controlled health record platform, has announced its next major growth phase outside its home country. Exhibiting as part of the UK Government pavilion hosted by the Department for Business, Innovation, Science and Trade (DBIST), the company is launching a strategic global expansion. Their target? The highly fragmented, deeply entrenched US health tech market.

With nearly 9 million users already managing their care through the platform in the UK, the company is not a typical startup seeking product-market fit. It is a tested, national-scale infrastructure looking to export a philosophical shift in data governance. As artificial intelligence and clinical research demand increasingly vast datasets, the Cambridge-based social enterprise is betting that explicit, granular patient consent is the only sustainable pipeline for the future of health innovation.

The Soft Power of Healthtech

The presence of the firm at HLTH Las Vegas under the DBIST banner highlights a broader strategy by the UK government to leverage its homegrown digital health successes as a form of technological soft power. Founded in 2008 by Dr. Mohammad Al-Ubaydli, the platform was built as a social enterprise driven by a singular mission: giving people direct access to, and understanding of, their health data.

Today, that mission has scaled massively. The platform is deeply integrated into core national services, including the NHS App in England and the NHS Wales App. By pulling data from public and private health providers, medical devices, and wearables into a single record controlled entirely by the patient, the system has achieved something historically elusive in healthcare: genuine, patient-mediated interoperability at scale.

"We are delighted to join the UK pavilion at HLTH Las Vegas," said Dr. Mohammad Al-Ubaydli, founder and CEO of Patients Know Best, in a statement regarding the expansion. "Our open platform has added a range of new partners in recent months, and we are coming to HLTH to find more, so that patients everywhere can use every digital service that helps them."

Exporting this model, however, requires more than government backing. It requires translating a system designed alongside a single-payer national health service into the complex, multi-payer, privatized reality of international healthcare.

Exporting Interoperability to a Walled Garden

Entering the US market places the British firm in direct competition—and potential collaboration—with some of the most entrenched players in global health IT. The American patient portal landscape is largely dominated by enterprise Electronic Health Record (EHR) vendors. Platforms like Epic’s MyChart are ubiquitous, but they are fundamentally tethered to the health systems that purchase them, often leaving patients to juggle multiple portals for different providers.

Meanwhile, consumer tech giants like Apple have made significant strides with Apple Health, utilizing Fast Healthcare Interoperability Resources (FHIR) standards to aggregate records on mobile devices. Yet, the broader ecosystem remains fractured. Federal initiatives like the Trusted Exchange Framework and Common Agreement (TEFCA) aim to create a nationwide floor for interoperability, but progress is slow, and the framework relies heavily on institutional networks rather than individual patient mediation.

To succeed stateside, the UK pioneer will need to navigate strict HIPAA regulations and prove its open architecture can seamlessly integrate with entrenched US systems. One US digital health analyst noted that while the concept of a truly patient-owned record is the "holy grail" of interoperability, the friction lies in adoption. Providers must be convinced to integrate, and patients must be motivated to actively manage their digital health vaults.

The Ethical Data Pipeline

Where the platform may find its most potent competitive advantage is not in competing with hospital portals, but in redefining how third-party innovators access medical data. Traditionally, digital health and life sciences companies have relied on complex, often opaque data-sharing deals between institutions to fuel their algorithms and research.

The British enterprise offers a radically different route: bypassing the institutional B2B data broker entirely. Over the last quarter, the platform has accelerated its open ecosystem by integrating a new wave of partners focused on self-management, AI, and clinical trials. Recent additions include GetMine, an encrypted health vault featuring a built-in AI health companion, and Emilia, an application dedicated to consultation transcription.

Crucially, these integrations operate on strict patient consent. Partners connect to the open architecture to offer their services, but the individual patient dictates whether to use them and precisely what data to share.

This model has profound implications for clinical research. The company recently launched contracted trial recruitment programs with clinical trial organizations Sano Genetics and Clerkenwell Health. By utilizing a consent-based model, these organizations can identify and recruit suitable candidates—such as those for Major Depressive Disorder or Parkinson's disease trials—directly through the platform. Patients who match trial criteria are presented with opportunities securely within their record, allowing them to opt-in based on a clear understanding of what data will be utilized.

The AI Era Demands a New Consent Standard

As the health tech industry rushes to integrate generative AI and predictive analytics, the ethical sourcing of training data has become a flashpoint. Patients and regulators alike are increasingly wary of how medical histories are being monetized or fed into algorithms without explicit permission.

In the US, several states have recently tightened regulations, now requiring written, revocable consent before AI tools can record or transcribe clinical therapy sessions. This shifting regulatory landscape transforms the consent-based architecture from a moral stance into a critical compliance asset. For companies building AI for health, partnering with a platform that guarantees data has been explicitly volunteered by the patient mitigates significant legal and reputational risks.

By arriving at HLTH Las Vegas with a proven, scalable model that prioritizes human agency over institutional data hoarding, the UK firm is challenging the foundational economics of the American health tech ecosystem. If they can successfully navigate the regulatory hurdles and establish strategic footholds with US-based AI and life sciences partners, they may not just export a software platform, but catalyze a necessary evolution in how the global healthcare industry values patient consent.